Edison Pharmaceuticals is a biotechnology company developing drugs to treat rare genetic diseases of children that impair energy metabolism. Founded in 2005 by Dr.'s Guy Miller and Sidney Hecht, the company's first drug candidate is entering clinical trials in Q3, 2008. Edison's core skills center on an understanding of the basic chemical properties underpinning the therapeutic and anti-aging properties of CoQ10. Edison is applying its understanding of these properties, to design, synthesize, test and develop novel and proprietary orally available CoQ10-based therapeutics directed at energy defects associated with inherited mitochondrial disease and diseases of aging.


Web site: http://www.edisonpharma.com

 

 

 

Twenty five short videos by Edison Pharmaceuticals are available at:

 

http://it.youtube.com/user/edisonpharma

 

 

Particularly interesting:

 

 

A0001 Starts Clinical Development

 

Guy Miller, Ph.D., M.D.
Founder and CEO
Edison Pharmaceuticals

 

http://it.youtube.com/watch?v=4Q_KnpsJ1Zo

 

 

 

Mitochondria are Central to Life

 

William Shrader, Ph.D.
V.P. of Research and Development
Edison Pharmaceuticals

 

http://it.youtube.com/watch?v=KemjZA-qEF

 

 

 

Humans are Small Power Plants

 

William Shrader, Ph.D.
V.P. of Research and Development
Edison Pharmaceuticals

 

http://it.youtube.com/watch?v=BTtgGzicf9c

 



The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!

https://www.amazon.com/Legacy-Marie-Schlau-collective-Friedreichs-ebook/dp/B01N28AFWZ

 

Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

https://www.irbbarcelona.org/en/news/international-patient-advocates-partner-to-fund-spanish-gene-therapy-project-to-treat

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:

https://www.irbbarcelona.org/en/news/new-research-front-to-tackle-friedreichs-ataxia
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.

 

 

Go to top